Bipolar Depression – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Bipolar depression is frequently misdiagnosed as unipolar depression due to the overlap in clinical symptoms between these two conditions. Patients may not recognize their 'high' periods as illness, leading them to seek assistance only during depressive episodes. As a result, bipolar depression often goes unrecognized for several years, especially in cases of bipolar II disorder, where hypomania episodes can be mistaken for a return to normal mood after depression. In over 50% of bipolar disorder cases, depression is the initial manifestation of the illness, creating a diagnostic challenge in distinguishing it from unipolar depression. The symptom profile includes psychomotor retardation, 'atypical' features such as increased appetite and excessive sleep (reverse neurovegetative), and sometimes psychotic symptoms. Episodes of bipolar depression tend to be more rapid in onset, more frequent, and shorter in duration than unipolar depression. However, in practice, there is often a mix of manic and depressive symptoms, making it challenging to differentiate unipolar and bipolar depression, particularly in the absence of obvious prior manic episodes. Clinical management is thus influenced by diagnostic uncertainty. Managing bipolar depression is further complicated by underdiagnosis, especially in the early stages when treatment response is most effective. Underdiagnosis and misdiagnosis result in inadequate and inappropriate treatment for bipolar depression. The most suitable treatment approaches approved by the US Food and Drug Administration (FDA) include the olanzapine–fluoxetine combination (OFC) and quetiapine.
Thelansis’s “Bipolar Depression Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential BIPOLAR DEPRESSION treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Bipolar Depression across the 8 MM market from the Centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Bipolar Depression Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment